NCT06795659 is a Phase 1, PHASE2 clinical trial of Esketamine (Intranasal Spray) in Post Traumatic Stress Disorder PTSD, sponsored by The University of Texas Health Science Center at San Antonio.

Who is sponsoring NCT06795659?

NCT06795659 is sponsored by The University of Texas Health Science Center at San Antonio.

What drugs are being tested in NCT06795659?

Interventions in NCT06795659: Esketamine (Intranasal Spray), Massed Prolonged Exposure (PE).

What condition does NCT06795659 study?

NCT06795659 studies Post Traumatic Stress Disorder PTSD.

Is NCT06795659 still recruiting?

NCT06795659 is currently completed. Last updated 28 January 2026.

Last reviewed 2026-01-28 · How we verify

NCT06795659

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)

Completed Phase 1, PHASE2 Last updated 28 January 2026

What this trial tests

Phase 1, PHASE2 trial testing Esketamine (Intranasal Spray) in Post Traumatic Stress Disorder PTSD in 4 participants. Completed in 16 January 2026.

Timeline

9 June 2025

Primary endpoint
16 January 2026

16 January 2026

Quick facts

Lead sponsor	The University of Texas Health Science Center at San Antonio
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	9 June 2025
Primary completion	16 January 2026
Estimated completion	16 January 2026
Sites	1 location across United States

Drugs / interventions tested

Esketamine (Intranasal Spray)
Massed Prolonged Exposure (PE)

Conditions studied

Post Traumatic Stress Disorder PTSD — all drugs for Post Traumatic Stress Disorder PTSD →

Sponsor

The University of Texas Health Science Center at San Antonio

Who can join

Adults 18 to 65, any sex, with Post Traumatic Stress Disorder PTSD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being done to see if Prolonged Exposure (PE), a well-researched, very effective individual (one-to-one) behavioral therapy designed to help people to directly deal with traumatic events they have suffered in the past, can be combined with intranasal esketamine (ketamine) for the treatment of posttraumatic stress disorder (PTSD) to enhance treatment benefits. Ketamine nasal spray is a drug approved by the U.S. Food \& Drug Administration (FDA) for treatment resistant depression. Combined with PE, intranasal ketamine may help to augment PE and further reduce participants' PTSD symptoms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Esketamine (Intranasal Spray)

Trials testing the same drug.

NCT02497287 — A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression · Phase 3 · completed

Other The University of Texas Health Science Center at San Antonio trials

Trials by the same sponsor.

NCT07280897 — SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial · NA · not yet recruiting
NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07056699 — SGLT2i, Pioglitazone, and Ketone Production in T1D · Phase 3 · not yet recruiting
NCT06609343 — Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis · Phase 1, PHASE2 · not yet recruiting
NCT07437053 — Sarcopenia in Chronic Kidney Disease (CKD) Patients · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06795659 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center at San Antonio
Last refreshed: 28 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06795659.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing